2019•Unpublished venueRequires access
Study on the diagnostic value of serum pepsinogen and gastrin-17 in gastric cancer and atrophic gastritis
Yunfei An, Fei Ding, Bei Cai, Wenling Zhao, Jing Hu, Zhuochun Huang, Lixin Li
Open publisher page 0 citations
Abstract
Objective
To investigate the level changes and clinical value of serum pepsinogen (PG) and gastrin-17 (Gastrin-17) in non-atrophic gastritis, atrophic gastritis and gastric cancer.
Method
Pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), gastrin-17 (G-17) and the PGⅠ/PGⅡ (PGR) levels were measured in 37 patients with non-atrophic gastritis, 37 patients with atrophic gastritis and 65 patients with gastric cancer by enzyme-linked immunosorbent assay.
Results
The PGⅠand PGR in the atrophic gastritis group were significantly lower than those in the non-atrophic gastritis group (P<0.05). The PGⅠand PGR levels in the gastric cancer group were significantly lower than those in non-atrophic gastritis group and atrophic gastritis group (P<0.05). The level of PGⅡ in the gastric cancer group was significantly higher than that in the non-atrophic gastritis group (P<0.05). The G-17 in the gastric cancer group was significantly higher than that that in the atrophic gastritis and non-atrophic gastritis group (P<0.05). The G-17 in the gastric antrum cancer group was significantly higher than that in the gastric body cancer group (P<0.05).
Conclusions
Pepsinogen and gastrin can be used as serological markers for screening atrophic gastritis and gastric cancer. Serum gastrin-17 has great clinical value in distinguishing gastric antrum and gastric body cancer.
Key words:
Pepsinogen; Stomach neoplasms; Atrophic gastritis; Gastrin-17